A robust prognostic gene expression signature for early stage lung adenocarcinoma

Marcin Krzystanek, Judit Moldvay, David Szüts, Zoltan Imre Szallasi, Aron Charles Eklund

    Research output: Contribution to journalJournal articleResearchpeer-review

    350 Downloads (Pure)


    Stage I lung adenocarcinoma is usually not treated with adjuvant chemotherapy; however, around half of these patients do not survive 5 years. Therefore, a reliable prognostic biomarker for early stage patients would be critical to identify those most likely to benefit from early additional treatments. Several studies have searched for gene expression prognostic biomarkers for lung adenocarcinoma, but these have not yielded a widely accepted prognosticator. We analyzed gene expression from seven published lung adenocarcinoma cohorts for which we included only stage I and II patients who were not given adjuvant therapy. Seven genes consistently obtained statistical significance in Cox regression for overall survival. The combined signature has a weighted mean hazard ratio of 3.2 in all cohorts and 3.0 (C.I. 1.3-7.4, p 
    Original languageEnglish
    JournalBiomarker Research
    Issue number4
    Number of pages7
    Publication statusPublished - 2016

    Bibliographical note

    © 2016 Krzystanek et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.


    • Early stage cancer
    • Gene expression
    • Lung adenocarcinoma
    • Prognostic biomarker

    Fingerprint Dive into the research topics of 'A robust prognostic gene expression signature for early stage lung adenocarcinoma'. Together they form a unique fingerprint.

    Cite this